Zeolitic Imidazolate Framework-8 as pH-Sensitive Nanocarrier for "Arsenic Trioxide" Drug Delivery.
arsenic
cancer
drug delivery
metal-organic frameworks
nanoparticle
Journal
Chemistry (Weinheim an der Bergstrasse, Germany)
ISSN: 1521-3765
Titre abrégé: Chemistry
Pays: Germany
ID NLM: 9513783
Informations de publication
Date de publication:
11 Oct 2019
11 Oct 2019
Historique:
received:
06
06
2019
revised:
16
07
2019
pubmed:
25
7
2019
medline:
16
11
2019
entrez:
24
7
2019
Statut:
ppublish
Résumé
Previous results revealed that arsenic trioxide might be used as promising therapeutic agent for the treatment of some solid tumours as atypical teratoid rhabdoid tumours (ATRT). However, in order to become an approved drug for solid tumour treatment, the active formulation has to get more efficient and feasible-but at the same time less toxic. One of the possibilities to achieve this dichotomy is to use nanomedicine tools. Herein, we report on the Zn-based metal-organic framework ZIF-8 (Zeolitic Imidazolate Framework-8) which turned out to be a promising candidate for the delivery of As
Identifiants
pubmed: 31336004
doi: 10.1002/chem.201902599
pmc: PMC6856809
doi:
Substances chimiques
Zeolites
1318-02-1
Polyethylene Glycols
3WJQ0SDW1A
Arsenic Trioxide
S7V92P67HO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13189-13196Subventions
Organisme : Else Kröner-Fresenius-Stiftung
ID : 2016_A181
Informations de copyright
© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
Références
Int J Nanomedicine. 2008;3(2):133-49
pubmed: 18686775
J Biomater Appl. 2016 Jul;31(1):23-35
pubmed: 27059495
Chem Rev. 2012 Feb 8;112(2):933-69
pubmed: 22098087
Nano Rev Exp. 2017 Jul 07;8(1):1335567
pubmed: 30410707
Chem Rev. 2017 Jun 28;117(12):8129-8176
pubmed: 28541694
Colloids Surf B Biointerfaces. 2014 Nov 1;123:506-14
pubmed: 25448719
Nature. 2003 Jun 12;423(6941):705-14
pubmed: 12802325
Chem. 2017 Apr 13;2(4):561-578
pubmed: 28516168
Cancer Res. 1989 Aug 15;49(16):4373-84
pubmed: 2545340
Nanomedicine (Lond). 2015 Jan;10(1):161-74
pubmed: 25597775
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Chemistry. 2019 Oct 11;25(57):13189-13196
pubmed: 31336004
Chem Commun (Camb). 2011 Feb 21;47(7):2071-3
pubmed: 21206942
J Adv Res. 2018 Jun 25;15:1-18
pubmed: 30581608
J Am Chem Soc. 2012 Sep 12;134(36):15016-21
pubmed: 22906112
Sci Rep. 2017 Aug 21;7(1):8912
pubmed: 28827686
Inorg Chem. 2013 Nov 4;52(21):12292-304
pubmed: 24147771
Small. 2018 Oct;14(40):e1801900
pubmed: 30091524
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
J Mater Chem B. 2018 Oct 28;6(40):6481-6489
pubmed: 32254655
Cancer Manag Res. 2016 Sep 16;8:115-125
pubmed: 27695363
Chem Soc Rev. 2017 Jun 6;46(11):3104-3107
pubmed: 28561090
Front Oncol. 2012 Sep 12;2:114
pubmed: 22988546
Chem Rev. 2012 Feb 8;112(2):1105-25
pubmed: 22070233
Dalton Trans. 2012 Jun 21;41(23):6906-9
pubmed: 22580798
Biotechnol Adv. 2014 Jul-Aug;32(4):693-710
pubmed: 24309541